Executives Join Cenduit’s Team

Cenduit announced today the addition of two new executives to its management team

Durham, North Carolina — April 23, 2008

Cenduit announced today the addition of two new executives to its management team, Jennifer Aquino, Vice President of Project Management, and Sharad Gupta, Vice President of Operations. Cenduit, an Interactive Response Technology (IRT) joint venture between Thermo Fisher Scientific and Quintiles, opens the door to a new level of clinical trial support by acting as the central conduit of data between the clinical supplies and the clinical development markets.

Jennifer Aquino will lead as the Vice President, Project Management, Worldwide. Ms. Aquino has diverse experience as a clinical trials professional with extensive expertise in project management, clinical data management, process definition and management and technology implementation. Prior to joining Cenduit, Jennifer was the Director of Business Solutions with Vertex Pharmaceuticals and Vice President, Voice and Data Systems for Perceptive Informatics, Inc. division of Parexel International. In her tenure at Perceptive Informatics, Jennifer defined and implemented the ePRO strategy for the corporation and managed the release of the first ePRO and Interactive Web Response System. In addition, she established and managed the project management team developing a project management methodology with key performance indicators that increased productivity and effectiveness. Ms. Aquino brings over 15 years of experience in business development, data and project management with her to Cenduit. “Jennifer is a valuable addition to our staff”, says Jogin Desai. “She offers strong leadership and creative thinking to drive growth and increased productivity”.

Sharad Gupta will oversee the worldwide operations of Cenduit as a member of executive team. Sharad is a visionary leader, strategic thinker and has a strong record of consistent profit and revenue growth. Sharad's most recent achievement, prior to joining Cenduit includes, leading an integrated team as the General Manager, Software Group, IBM India Pvt. Ltd in Mumbai. As Managing Director India Operations, Webify Solutions Inc., he successfully built the company from conception, managed and led the team to ultimately oversee the acquisition by IBM in August 2006. As an entrepreneur, Sharad co-founded Amex Information Technologies Ltd., Mumbai, in 1996 in which he led the Sales and Marketing effort, established offices in UK and Europe, and successfully took the company to IPO in 1999, listed at Bombay Stock Exchange. He has held several high profile positions in a career spanning 25 years in the IT industry.

"I have a great deal of respect for Sharad" says Jogin Desai, CEO. "Sharad is an Executive with highly diversified business experience in all aspects of Operations and Management. I am confident his leadership will strongly enhance Cenduit's operations and our ability to grow business." “We at Cenduit look forward to welcoming both Sharad and Jennifer to our executive team. I am confident these additions will have a positive impact here at Cenduit “, added Jogin Desai.

About Cenduit: Cenduit, founded in 2007 through a joint venture of Thermo Fisher and Quintiles, provides a proprietary Interactive Response Technology (IRT) that transform s drug development through an innovative class of advanced e-Clinical software that connects sponsors, investigator sites, clinical trial suppliers, and clinical research organizations faster and more effectively than ever to enable more confident decision-making. IRT is a technology platform that integrates patient interaction systems through a combination of telephone response, Web interface and handheld electronic patient diaries. The use of IRT is expected to grow as pharmaceutical companies look to streamline and better control increasingly complex drug development process. Headquartered in Durham, NC, Cenduit employs180 professionals throughout the world with offices in the United Kingdom, India, and Switzerland. Cenduit’s state-of-the-art IRT and highly-trained staff, offers unparalleled support through agile responsiveness allowing us to optimize opportunities within this intricate process through a seamless interface with all providers involved in a clinical program.
Thermo Fisher Scientific and Quintiles Create Joint Venture to Provide Integrated Response Technology Services (21-May-2007)

WALTHAM, Mass., May 21 /PRNewswire-FirstCall/ -- Thermo Fisher Scientific Inc. (NYSE: TMO) and Quintiles Transnational Corp. today announced the creation of a joint venture, called Cenduit, that provides seamless, integrated Interactive Response Technology (IRT) services during the clinical trial phase of drug development. IRT is a technology platform that integrates patient interaction systems through a combination of telephone response, Web interface and handheld electronic patient diaries. The use of IRT is expected to grow as pharmaceutical companies look to streamline and better control increasingly complex drug development processes.

"Our companies have been looking for an opportunity to leverage the particular service strengths we bring to the drug development process," said Marijn E. Dekkers, president and chief executive officer of Thermo Fisher Scientific. "With Cenduit, we have combined two leaders -- the clinical supply chain expertise of our Fisher Clinical Services business with the clinical development expertise of Quintiles -- to offer a scalable, seamless technology platform." The name "Cenduit" signifies the channel through which information can move directly and freely.

Thermo Fisher contributes to the joint venture its Fisher Clinical Services IRT operations in three locations -- Horsham, U.K.; Allentown, Penn., USA; and Basel, Switzerland. Quintiles brings its IRT operations in Bangalore, India, and Research Triangle Park, N.C., USA, which will also serve as Cenduit's headquarters.
Jogin Desai, chief executive officer of Cenduit, said, "This joint venture brings together best-in-class technology, exceptional customer service and global clinical trial expertise to give biotechnology and pharmaceutical companies a seamless, integrated 'one-stop' service for support of their clinical development programs. Our efficiency and experience in IRT services and clinical project management offers the drug development industry a conduit to the broadest, most accurate, real-time view of every detail in the process - and a very competitive solution." Desai previously served as executive director of Quintiles Cardiac Safety Services.

About Quintiles

Quintiles Transnational Corp. is powering the next generation of healthcare by providing a broad range of professional services in drug development, financial partnering and commercialization for the biotechnology and healthcare industries. With 17,000 employees and offices in more than 50 countries, it is focused on providing customer-centric solutions that are the gold standard of the industry. For more information, please visit the company's Web site at http://www.quintiles.com.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is the world leader in serving science, enabling our customers to make the world healthier, cleaner and safer. With an annual revenue rate of more than $9 billion, we employ 30,000 people and serve over 350,000 customers within pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as environmental and industrial process control settings. Serving customers through two premier brands, Thermo Scientific and Fisher Scientific, we help solve analytical challenges from routine testing to complex research and discovery. Thermo Scientific offers customers a complete range of high-end analytical instruments as well as laboratory equipment, software, services, consumables and reagents to enable integrated laboratory workflow solutions. Fisher Scientific provides a complete portfolio of laboratory equipment, chemicals, supplies and services used in healthcare, scientific research, safety and education. Together, we offer the most convenient purchasing options to customers and continuously advance our technologies to accelerate the pace of scientific discovery, enhance value for customers and fuel growth for shareholders and employees alike. Visit http://www.thermofisher.com.